FdaApplication
NDA 210274
Identifiers
- fda_app_no: NDA210274
Properties
| Property | Value |
|---|---|
| applicant_name | ZHEJIANG NOVUS PHARMACEUTICALS CO LTD |
| application_type | NDA |
| approval_date | 2023-01-20 |
Products (7)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 1.5MG BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 10GM BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 750MG BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 1GM BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | EQ 1.25GM BASE/VIAL | POWDER;INTRAVENOUS, ORAL |
7 products